Valrocemide-TV1901-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEValrocemideCat. No.: HY-100379CAS No.: 92262-58-3Synonyms: TV1901分式: CHNO分量: 200.28作靶點(diǎn): Others作通路: Others儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗 DMSO : 100 mg/mL (499.30 mM)* means soluble

2、, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 4.9930 mL 24.9650 mL 49.9301 mL5 mM 0.9986 mL 4.9930 mL 9.9860 mL10 mM 0.4993 mL 2.4965 mL 4.9930 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實(shí)驗請根據(jù)您的實(shí)驗動物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前請先配制澄清的儲備液，再依次添加助溶?為保證實(shí)驗結(jié)果的可靠性，體內(nèi)實(shí)驗的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；

3、澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.75 mg/mL (13.73 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.75 mg/mL (13.73 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE3

4、. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.75 mg/mL (13.73 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Valrocemide（TV1901）種有前景的抗癲癇候選藥物，具有泛的抗驚厥活性。體內(nèi)研究 In mice, valrocemide affords complete protection against maximal electroshock-, pentylenetetrazole-,picrotoxin-, and bicuculline-induced seizures a

5、nd 6-Hz “psychomotor” seizures with median effective dose(ED50) values of 151, 132, 275, 248, and 237 mg/kg, respectively. Valrocemide is also effective in preventingsound-induced seizures in Frings audiogenic-seizure susceptible mice (ED50, 52 mg/kg). The medianneurotoxic dose in mice is 332 mg/kg.

6、 After oral administration to rats, valrocemide is active in the MES test,with an ED50 of 73 mg/kg, and the median neurotoxic dose is 1,000 mg/kg. Intraperitoneal administration of300 mg/kg of valrocemide to hippocampal kindled SpragueDawley rats block generalized seizures andshorten the afterdischa

7、rge duration significantly. Valrocemide also provides complete protection from focalseizures in the corneally kindled rats (ED50, 161 mg/kg) 1.PROTOCOLAnimal Rats: Effect of valrocemide on the afterdischarge threshold in hippocampal kindled rats is evaluated in ratsAdministration 1 kindled according

8、 to this procedure. On the day of the test, the individual rats afterdischarge threshold isdetermined by increasing the current intensity stepwise until the rat displayed an electrographicafterdischarge with duration of 4 s. For afterdischarge threshold determination, the initial stimulation iscondu

9、cted at 20 A and increased in 10-A increments every 12 min until an afterdischarge is elicited. Afteradministration of valrocemide, the individual rats afterdischarge threshold is redetermined at times 0.5, 1, 2,and 4 h; ADD and BSS are recorded at each time point and compared with the control value

10、s obtainedbefore drug administration. The criteria for seizure scoring is as described earlier for corneally kindledanimals 1.Mice: The intravenous (i.v.) pentylenetetrazole seizure threshold test (i.v. Met) also is used. At the TPE ofvalrocemide, infusion (0.34 ml/min) of 0.15% heparinized solution

11、 of pentylenetetrazole (0.5%) is started intothe tail vein of a mouse, and the times to the appearance of the first myoclonic jerk and the subsequentsustained clonic seizure are recorded. A group of 10 drug-treated (132 mg/kg valrocemide, i.p.) mice iscompared with 10 vehicle-treated controls. The t

12、ime is converted to the dose of pentylenetetrazole in mg/kg.The i.v. Met test is performed according to the same procedure also after prolonged administration ofvalrocemide daily, i.p. (132 mg/kg) for 5 consecutive days 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Isoherranen N, et al. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia. 2001 Jul;42(7):831-6.McePdfHeight2/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE